Cambridge Investment Research Advisors’s Transmedics TMDX Stock Holding History

Cambridge Investment Research Advisors’s Portfolio TMDX Stock Details TMDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.09M	Sell	16,456 -989	-6%	-$83.7K	﹤0.01%	2068
2026 Q1	$1.73M	Sell	17,445 -224	-1%	-$29.2K	﹤0.01%	1705
2025 Q4	$2.15M	Buy	17,669 +1,064	+6%	+$134K	0.01%	1463
2025 Q3	$1.86M	Buy	16,605 +1,477	+10%	+$173K	0.01%	1558
2025 Q2	$2.03M	Buy	15,128 +3,436	+29%	+$377K	0.01%	1429
2025 Q1	$787K	Buy	11,692 +4,643	+66%	+$319K	﹤0.01%	2053
2024 Q4	$440K	Buy	7,049 +4,445	+171%	+$414K	﹤0.01%	2534
2024 Q3	$409K	Hold	2,604	–	–	﹤0.01%	2573
2024 Q2	$392K	Sell	2,604 -581	-18%	-$69.7K	﹤0.01%	2487
2024 Q1	$235K	Buy	+3,185	New	+$263K	﹤0.01%	2887

Other funds holding TMDX

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

ZCI

Zevenbergen Capital Investments Edmonds, Washington $4.38B AUM 56.68% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return

PCM

Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

TFCM

Taylor Frigon Capital Management Scottsdale, Arizona $214M AUM 47.29% 1-Year Est. Return

GIA

Gladstone Institutional Advisory Palm Beach Gardens, Florida $3.16B AUM 29.04% 1-Year Est. Return

DADC

D.A. Davidson & Co Great Falls, Montana $18.1B AUM 24.63% 1-Year Est. Return

STAS

Strong Tower Advisory Services Minneapolis, Minnesota $558M AUM 13.89% 1-Year Est. Return

Cambridge Investment Research Advisors's TMDX Position: Q2 2026 in Review

Cambridge Investment Research Advisors reduced its Transmedics (TMDX) stake by 5.7% in Q2 2026, selling an estimated $83.7K and leaving 16,456 shares worth $1.09M. The position accounts for ﹤0.01% of the portfolio, ranked #2068.

Cambridge Investment Research Advisors first reported a position in TMDX in Q1 2024 and has held it in 10 quarters since. The position peaked at $2.15M in Q4 2025. 87 funds tracked by Wall St. Rank hold TMDX as of Q2 2026.

Cambridge Investment Research Advisors held 16,456 shares of Transmedics worth $1.09M as of Q2 2026.
Cambridge Investment Research Advisors sold 989 Transmedics shares in Q2 2026, an estimated $83.7K.
Transmedics made up ﹤0.01% of Cambridge Investment Research Advisors's portfolio in Q2 2026, its #2068 holding.
Cambridge Investment Research Advisors first reported a position in Transmedics in Q1 2024 and has held it in 10 quarters since.
Cambridge Investment Research Advisors's Transmedics position peaked at $2.15M in Q4 2025.
87 funds tracked by Wall St. Rank held Transmedics as of Q2 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.